We work with partners worldwide across the continuum of healthcare to create unique drug delivery solutions for metabolic disease that bring progress to life for patients
One of the greatest opportunities we see for both our pharmaceutical partners and patients is the ability to improve the management of metabolic diseases like diabetes. Our biocompatible materials for drug delivery can enable long-duration therapies – with reduced dosing frequency and potentially increased patient adherence.
We work with partners worldwide across the continuum of healthcare to create unique drug delivery solutions for metabolic disease that bring progress to life for patients
15+ Years
Of experience in sustained drug delivery applications.
30+ Years
Of experience working with the world’s leading pharmaceutical companies.
150+ Years
Of combined scientific discovery and heritage as part of dsm-firmenich.
Our TheraPEA™ polyester amide platform is unlocking entirely new therapeutic opportunities for the pharmaceutical industry through its ability to achieve multi-month, controlled drug release.
This highly tunable biomaterial has a zero-order degradation profile and good correlation in-vitro and in-vivo up to 180 days. Furthermore, the unique chemistry of TheraPEA™ changes the game even further through its compatibility with a wide range of challenging Active Pharmaceutical Ingredients.
By developing customized drug delivery solutions with our partners in this way, we can enable longer duration therapies for patients with the potential to increase therapy adherence – and allow for improved clinical outcomes, better healthcare economics and significantly less medical waste.
Learn more about our drug delivery solutions.
In the treatment of diabetes (Type II) and obesity, our team can work with you to create long-acting therapies in both implantables and long-acting injectables. However, the potential benefits of our TheraPEA™ solution extends even further.
For example, integrating this unique biomaterial into new pharmaceutical formulations unlocks the potential to increase IP protection and extend the lifetime of branded sales.
Looking for more information on how our drug delivery solutions for metabolic disease management can help you tackle unmet needs?
Overcoming limitations in sustained release drug delivery
TheraPEA™ Brochure